Sino Biopharmaceutical’s Rovadicitinib Tablet Receives Landmark Approval in China

Key Highlights and Investor-Relevant Insights

• First-in-Class Approval: Sino Biopharmaceutical Limited (HKEX: 1177) announced that its innovative drug, rovadicitinib tablet (Trade name: Anxu®), has been approved for marketing by the National Medical Products Administration (NMPA) of China.
• Indication and Market Potential: Rovadicitinib is indicated as a first-line treatment for adult patients with intermediate-2 or high-risk primary myelofibrosis (PMF), post-polycythemia vera myelofibrosis (PPV-MF), or post-essential thrombocythemia myelofibrosis (PET-MF).
• Breakthrough Mechanism: This is a global first-in-class small-molecule inhibitor targeting both JAK and ROCK pathways, offering dual therapeutic effects: anti-inflammation and anti-fibrosis.
• Strong Clinical Results: In a Phase II, multicenter, randomized, double-blind clinical trial (TQ05105-II-01), rovadicitinib demonstrated superior efficacy and a favorable safety profile compared to hydroxyurea.
• Large and Growing Market: The prevalence of myelofibrosis (MF) in China is rising rapidly, with more than 67,000 patients in 2025 and a projected 300,000 patients by 2030.
• Pipeline Expansion: Rovadicitinib is also being developed for chronic graft-versus-host disease (cGVHD), advancing to Phase III trials in China and Phase II trials in the US.

Detailed Analysis for Shareholders

1. Regulatory Approval and Market Opportunities

The approval of rovadicitinib for marketing in China marks a significant milestone for Sino Biopharmaceutical. As a national Category 1 innovative drug developed independently by the company, this approval not only validates the Group’s R&D capabilities but also opens the door to a rapidly expanding patient pool. With an aging population, the number of MF cases is expected to surge, offering substantial revenue potential.

2. Clinical Efficacy and Safety Profile

In the pivotal Phase II trial, rovadicitinib outperformed hydroxyurea in intermediate-2 or high-risk myelofibrosis:

• Spleen Volume Reduction (SVR35): 58.33% of patients achieved ≥35% reduction in spleen volume at week 24 (as assessed by independent radiology review), with 63.89% achieving this at any time point. The average duration of benefit was 8.31 months.
• Symptom Score Improvement (TSS50): 77.78% of patients had ≥50% improvement in total symptom score.
• Safety: Well-tolerated with a Grade ≥3 adverse event rate of ~40% (anemia also ~40%). Treatment discontinuation was low (6.7%), significantly lower than seen with ruxolitinib, a current standard of care.

This combination of efficacy and safety supports the potential for strong uptake once launched.

3. Disease Landscape and Unmet Needs

MF is a rare but serious myeloproliferative neoplasm, with most patients in China diagnosed at an advanced stage. There is currently no curative therapy available; treatment is focused on symptom management and delaying disease progression. Rovadicitinib’s dual action (anti-inflammation and anti-fibrosis) could position it as a new standard of care, especially given its efficacy and safety advantages.

4. Pipeline Progress and Expansion Potential

Beyond MF, rovadicitinib is also being developed as a treatment for chronic graft-versus-host disease (cGVHD). In China, it has entered Phase III trials and was included in the Breakthrough Therapy Designation (BTD) process, signaling regulatory recognition of its potential to address serious unmet needs. In the United States, Phase II studies have been approved, opening additional international market opportunities.

5. Leadership and Corporate Governance

The announcement was made under the leadership of Chairwoman Theresa Y Y Tse, with a board comprising experienced executive and independent non-executive directors, underscoring Sino Biopharmaceutical’s strong governance and commitment to innovation.

Potential Share Price Impact and Investor Considerations

This announcement is highly price-sensitive and likely to be positively received by the market for several reasons:

• The first-in-class status of rovadicitinib could command premium pricing and reimbursement levels in China.
• The large and rapidly growing MF patient population underlines the significant revenue opportunity.
• Pipeline expansion into cGVHD and progress in the US create additional upside optionality.
• Clinical data suggests a competitive advantage over existing therapies, which could drive market share gains.

Investors should closely monitor further updates regarding the commercial launch, pricing decisions, and progress in cGVHD and international trials.

Disclaimer: This article is for informational purposes only and does not constitute investment advice. Investors should conduct their own research or consult a professional advisor before making investment decisions regarding Sino Biopharmaceutical Limited or any other security. The author and publisher accept no liability for actions taken based on this report.

View SINO BIOPHARM Historical chart here